Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
Stock Information for Zynerba Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.